MO1000MAINTENANCE IMMUNOSUPPRESSIVE THERAPY IN PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION
| Autor: | N. Braiek, Taieb Ben Abdallah, Mohamed Mongi Bacha, Fethi Ben Hmida, S. Fattoum, Tasnim Mosbehi, Ezzedine Abderrzhim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Nephrology Dialysis Transplantation. 36 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/gfab111.0024 |
| Popis: | Background and Aims Acute rejection (AR) is a redoubtable immunological complication after kidney transplantation (KT). Maintenance immunosuppressive treatment (IS) is a corner stone in prevention of AR. The aim of this study was to define the role of different maintenance IS in preventing AR. Method It was a longitudinal, retrospective, analytical study including kidney transplant patients followed up in our department between 1986 and 2019. Our population was divided in 2 groups: group A (129 KT complicated by at least one episode of AR) and group B (491 KT not complicated by AR). Results All patients received low dose of corticosteroids (CS) in their IS. Calcineurin inhibitors (CI) were not prescribed in first intention in 33,3% of groups A patients versus 13,2% in group B. Cyclosporin A (CsA) was prescribed in first intention in 57,4% of group A patients versus 45,7% in group B. Tacrolimus was prescribed in first intention in 9,3% of group A patients versus 41,1% in group B (p All patients received Atimetabolite (AM) in their IS. In first intention, Azathioprin was prescribed in 73,6 % of group A patients and Mycophenolate Mofetil (MMF) was prescribed in 78,6% of group B patients ( In first intention, maintenance IS consisted in low dose corticosteroids (CS) associated with AM in 13,5% of our patients. CI was associated to CS and AM in 86,5% of patients. Tritherapy was significantly more used than biotherapy in group A (p Conclusion Maintenance IS therapy must be well chosen according to immunological risk in order to prevent AR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|